Mitral Valve Disease
As an extension of the COAPT RCT trial, COAPT CAS study will be conducted after COAPT enrollment is complete under the same investigational device exemption (IDE(G120024)). The objective of this study is to evaluate the MitraClip® NT System for the treatment of clinically significant functional mitral regurgitation (FMR) in symptomatic heart failure subjects who are treated per standard of care and who have been determined by the site's local heart team as not appropriate for mitral valve surgery.
Principal Investigator: Paul Grayburn, MD
Locations: Baylor Heart and Vascular Hospital
Sponsor: Abbott Vascular
IRB Number: 012-111
Trial Status: Enrolling
Exclusions: Adults only
Change in Care: Participating may change your care
Brittany Zingler, RN469.814.4737Brittany.Zingler@BSWHealth.org
Necole Kell, RN469.814.4871Necole.Kell@BSWHealth.org
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) (COAPT)
Get Detailed Information On Clinicaltrials.gov »
Physicians are members of the medical staff at one of Baylor Scott & White Health's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor Scott & White The Heart Hospital – Plano or Baylor Scott & White Health.